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Aims Recent studies showed that polymorphisms on chromosome 9p21 are associated with coronary heart disease (CHD),
but few studies examined the association with heart failure (HF), stroke, or other subclinical atherosclerotic diseases. We
tested the association of chromosome 9p21 polymorphisms with non-coronary atherosclerotic diseases.
Methods
and results
We studied 4018 African-American and 11 085 white participants from the Atherosclerosis Risk in Communities
Study, aged 45–64 at baseline (1987–89). We examined associations of rs10757274 and rs2383206 polymorphisms
with incident HF through 2005 and ischaemic stroke through 2004, and with prevalent carotid atherosclerosis and
peripheral artery disease (PAD) at baseline. The GG genotype of rs10757274 was associated with increased HF
risk for whites. This association seemed independent of the established link between rs10757274 and clinical
CHD, although an impact of rs10757274 on subclinical CHD leading to HF is not eliminated. Among whites, GG
homozygotes were at weakly increased carotid atherosclerosis risk. There seemed to be no associations for ischae-
mic stroke or PAD. The results were essentially similar for rs2383206.
Conclusion The GG genotype of rs10757274 on chromosome 9p21, which has been shown to increase CHD risk, is also associ-
ated with increased HF risk among whites. It is weakly or not associated with several other atherosclerosis outcomes.
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Introduction
Recently, two reports1,2 independently identified a relatively strong
association of coronary heart disease (CHD) in whites with a
common allele represented by single-nucleotide polymorphisms
(SNPs) (rs2383206, rs10757274, rs10757278, or other nearby
SNPs within a genomic region of 100 kb). This genomic region
contains no annotated genes, but is located near the CDKN2A/B
gene on chromosome 9p21. This locus seems to increase CHD
risk independently of traditional coronary risk factors and indepen-
dently of a nearby SNP (rs10811661) associated with diabetes.3– 5 A
recent report showed that this variant may also increase the risk of
aortic and cerebral aneurysms,6 thus implicating altered vascular
structural integrity as one causal mechanism. More recently,
another study indicated that this area of SNPs influences carotid
atherosclerosis development and progression.7 To further explore
the link between this chromosome 9p21 variant and cardiovascular
disease, we prospectively examined the associations of the
rs10757274 and rs2383206 polymorphisms, which were identified
by a previous consortium,1 including Atherosclerosis Risk in Com-
munities (ARIC), with incident heart failure (HF) and ischaemic
stroke, as well as the cross-sectional prevalence of carotid athero-
sclerosis and peripheral artery disease (PAD) in the ARIC cohort.
Methods
Study cohort
The ARIC study cohort comprised a community-based sample
of 15 792 persons from four research field centres: Forsyth County,
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NC; the city of Jackson, MS (African-Americans only); northwestern
suburbs of Minneapolis, MN; and Washington County, MD. Participants
were 45–64 years of age at the baseline examination (1987–89).
The ARIC study protocol was approved by each field centre’s
institutional review board. After written informed consent was
obtained, participants underwent a baseline clinical examination.
Only African-Americans and whites were included in the present
study.
Participants were genotyped for the rs10757274 and rs2383206
single-nucleotide polymorphism (SNPs) using the TaqMan assay
system (Applied Biosystems, Foster City, CA, USA), as reported pre-
viously.1 The agreement between replicate pair was 98.2% for
rs10757274 and 94.2% for rs2383206. Methods for measuring other
risk factors in the ARIC study have been described elsewhere.8 For
exclusion, we defined prevalent CHD as the presence of a myocardial
infarction on the baseline electrocardiogram, or a self-reported history
of myocardial infarction or coronary revascularization; stroke as a
reported history of physician diagnosed stroke; and HF as reported
current medication use for HF, or having manifest HF as defined by
Gothenburg criteria9 stage 3.
Carotid intima-media thickness (IMT) was measured using B-mode
ultrasound during the baseline examination in the bilateral common
(optimal angle), bulb, and internal carotid arteries IMT, using a standar-
dized protocol.10 For this analysis, we used the mean of these six
values. Carotid atherosclerosis was defined as IMT .1.0 mm or the
presence of carotid plaque or shadowing. Ninety-three per cent of
participants had IMT measurement. Ankle–brachial blood pressure
index was also measured, using one random leg, in the baseline exam-
ination for 96% of participants. An ankle–brachial index of ,0.9 and/
or the presence of claudication based on the Rose Intermittent Clau-
dication questionnaire11 was considered PAD.
Participants were followed for incident cardiovascular events,
through 2004 for stroke and through 2005 for CHD and HF, via
annual telephone contact and surveillance of hospital and death
records. Cases of HF, ischaemic stroke, and CHD were identified
and classified.12 –14 Briefly, incident HF was defined by the first HF hos-
pitalization (ICD-9 code 428 in any position), or any deaths where the
death certificate included an HF code (code 428, ICD-9 or I50,
ICD-10, in any position). Ninety-four per cent of cases were identified
by hospitalization and 6% by death certificate.12 Non-hospitalized,
non-fatal HF was not captured. Strokes were classified according to
published criteria based on the occurrence and duration of neurologi-
cal signs and symptoms, the results of neuroimaging and other diagnos-
tic procedures, and treatments provided. Strokes secondary to trauma,
neoplasm, haematological abnormality, infection, or vasculitis were not
counted, and a focal deficit lasting ,24 h was not considered a stroke.
Incident CHD was defined as a definite or probable hospitalized myo-
cardial infarction, silent myocardial infarction by electrocardiogram, or
coronary revascularization.14
Statistical analyses
Of the 15 744 African-Americans and whites in ARIC, we excluded
persons with missing DNA or no consent for DNA use (n ¼ 44
excluded). Persons with missing SNP data were also excluded (n ¼
597 for rs10757274 and n ¼ 1133 for rs2383206). Thus, we included
15 103 subjects (4018 African-American and 11 085 whites) in the
rs10757274 analysis. Differences in baseline characteristics according
to rs10757274 SNPs were tested by analysis of variance, x2, or
Kruskal–Wallis rank tests. For incident HF and stroke analyses, we
further excluded persons who reported a baseline history of CHD,
stroke or HF, or missing HF (n ¼ 1723 excluded). For incidence ana-
lyses involving rs10757274, 13 380 (3499 African-Americans and
9881 whites) subjects were followed-up from baseline in 1987–89
to the first endpoint, death, loss to follow-up, or the end of 2004 or
2005. Age- and sex-adjusted and multivariable-adjusted hazard ratio
(HR) and 95% confidence interval (CI) of HF and ischaemic stroke
were calculated according to genotypes using race-specific Cox pro-
portional hazard models. The proportional hazards assumption was
tested using cross-product terms with survival time and was not vio-
lated for any SNPs. A few covariates in the multivariable models vio-
lated the proportional hazards assumption, but this did not affect
the SNP-phenotype results. Linearity of covariates included in the mul-
tivariable Cox models with estimated hazards was confirmed by testing
and rejecting quadratic terms for each continuous covariate, as they
did not affect the SNP associations. The HR for HF was also calculated
after censoring for incident CHD. For prevalent carotid atherosclerosis
and PAD, no further exclusions were made (i.e. prevalent CHD,
stroke, HF, carotid atherosclerosis, and PAD were included in the
analysis), and odds ratio (OR) and 95% CIs were calculated according
to genotypes using race-specific logistic regression models. For
rs10757274 analyses, 14 009 subjects had IMT data, and 14 544 sub-
jects had PAD information. Differences in mean carotid IMT were
tested by analysis of covariance, and means were presented in the
mean population profile for all covariates. In the multivariable
models, we adjusted for baseline values of age, sex (dichotomous),
body mass index, systolic blood pressure, antihypertensive medication
use (dichotomous), plasma total and high-density lipoprotein choles-
terol, diabetes (dichotomous), smoking status (never, past, or
current), cigarette years, ethanol and energy intake, education level
(below high school graduation, high school graduation, or above
that), and sports index (0.0–1.9, 2.0–2.4, 2.5–2.9, 3.0–5.0). Because
the studied SNPs have been additively associated with CHD,1 we
assumed an additive model in the present analyses, and trends in
associations were tested using the number of alleles as continuous
variables (i.e. 0 for AA, 1 for AG, 2 for GG). Interactions of baseline
age (45–54 or 55–64), sex, current smoking, prevalent obesity
(defined as body mass index 30 kg/m2), hypertension (systolic
blood pressure 140 mmHg and/or diastolic blood pressure
90 mmHg and/or use of antihypertensive medication), diabetes
(fasting glucose 126 mg/dL or non-fasting glucose 200 mg/dL,
and/or history of diagnosed diabetes and/or use of diabetic
medication), hypercholesterolaemia (plasma cholesterol of 240 mg/
dL or use of cholesterol-lowering medication) with rs10757274 geno-
types in relation to incident HF were tested using cross-product terms.
Free software15 was used to create forest plots (Supplementary
material online, figures). We used SAS version 9.1.3 Service Pack 4
(SAS Institute Inc., Cary, NC, USA) for the analyses. All probability
values for statistical tests were two-tailed and values of P , 0.05
were regarded as statistically significant except for interaction tests.
For interactions, we regarded P , 0.007 ( ¼ 0.05/7) as significant
since we stratified by seven effect modifiers without a priori hypotheses.
Results
Distributions of the rs10757274 and rs2383206 genotypes did not
deviate from Hardy–Weinberg equilibrium for either
African-Americans (P ¼ 0.11 for rs10757274 and P ¼ 0.61 for
rs2383206) or whites (P ¼ 0.67 for rs10757274 and P ¼ 0.12 for
rs2383206). Other than race, few baseline risk factors differed
by genotype (Table 1). At baseline, 690 participants had PAD
(prevalence ¼ 5%) and 4350 had carotid atherosclerosis
(prevalence ¼ 31%). During a median of 17 years of follow-up
(inter-quartile range ¼ 16–18), 1331 incident HF events (6.4 per
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Table 1 Baseline characteristics according to rs10757274 genotypes, ARIC, 1987–89
Number rs10757274
African-Americans Whites
AA AG GG P-valuea AA AG GG P-valuea
2482 1330 206 2921 5517 2647
Age (year) 53.4 (5.8) 53.6 (5.8) 54.2 (6.0) 0.11 54.3 (5.8) 54.4 (5.7) 54.3 (5.8) 0.86
Male (%) 37.6 38.8 40.3 0.63 47.6 47.1 46.7 0.79
Body mass index (kg/m2) 29.6 (6.1) 29.7 (6.1) 29.3 (6.1) 0.60 27.2 (5.0) 27.0 (4.8) 26.9 (4.8) 0.01
Systolic blood pressure (mmHg) 129 (21) 129 (22) 128 (23) 0.86 119 (17) 118 (17) 118 (17) 0.39
Diastolic blood pressure (mmHg) 80 (12) 80 (12) 79 (13) 0.24 72 (10) 71 (10) 71 (10) 0.27
Antihypertensive medication (%) 43.8 43.1 40.8 0.68 25.2 25.8 26.7 0.45
Plasma total cholesterol (mg/dL) 215 (45) 214 (46) 215 (46) 0.97 215 (39) 215 (41) 214 (40) 0.39
Plasma HDL cholesterol (mg/dL) 55 (18) 54 (17) 54 (17) 0.30 50 (17) 51 (17) 50 (16) 0.71
Plasma triglyceride (mg/dL)b 96 (71–133) 97 (72–135) 98 (72–137) 0.60 116 (82–168) 114 (82–163) 114 (82–164) 0.74
Diabetes (%) 19.5 19.1 23.2 0.39 8.9 9.2 9.1 0.88
Sports index (range 1–5)b 2.0 (1.8–2.5) 2.0 (1.8–2.5) 2.0 (1.8–2.5) 0.96 2.5 (2.0–3.0) 2.5 (2.0–3.0) 2.5 (2.0–3.0) 0.04
Education (.high school graduate, %) 37.0 38.3 35.1 0.60 46.9 46.8 45.8 0.65
Current smoking (%) 29.4 30.4 31.4 0.71 24.9 24.9 24.4 0.88
Cigarette-yearsb 10 (0–345) 56 (0–400) 0 (0–375) 0.11 120 (0–600) 150 (0–620) 163 (0–600) 0.27
Alcohol intake (g/week)b 0.0 (0.0–13.2) 0.0 (0.0–0.0) 0.0 (0.0–13.2) 0.51 0.0 (0.0–51.8) 0.0 (0.0–54.2) 0.0 (0.0–51.8) 0.39
Total energy intake (Kcal/day) 1593 (622) 1571 (618) 1594 (647) 0.59 1651 (608) 1635 (600) 1626 (608) 0.30
Values are means (standard deviations) or percentages, except for variables indicated with ‘b’.
aP-values for overall difference.







1000 person-years) occurred. For ischaemic stroke, 524 events
(2.6 per 1000 person-years) occurred during a median of 16
years of follow-up (inter-quartile range ¼ 15–17).
As Table 2 shows, compared with the AA genotype, the risk of
HF was greater among carriers of the GG genotype of rs10757274
among whites [multivariable HR ¼ 1.30 (1.07–1.58)]. A similar
tendency was observed for African-Americans, but was not statisti-
cally significant. The association observed in whites was slightly
attenuated, but still statistically significant, when CHD events
were censored at their occurrence. Ischaemic stroke and PAD
were not associated with rs10757274 genotype in either
African-Americans or whites. A weak association was observed
for carotid atherosclerosis among whites [OR for GG genotype ¼
1.14 (1.00–1.29)]. For rs2383206, the associations were similar to
those for rs10757274 (Supplementary material online, Table).
These two SNPs were highly linked with each other among whites
(r2 ¼ 0.86) and modestly among African-Americans (r2 ¼ 0.36).
Since associations were primarily observed between rs10757274
and HF, we further tested the interactions of genotype with age, sex,
current smoking, obesity, hypertension, diabetes, and hypercholes-
terolaemia (Supplementary material online, Figures S1 and S2). In
African-Americans, an association between rs10757274 and HF
was observed among men, but not for women, although the
interaction (P ¼ 0.02) was not quite statistically significant by
our P , 0.007 criterion. Among African-American men, the
multivariable-adjusted HRs (95% CIs) for HF were 1.18
(0.84–1.65) for the AG genotype and 2.15 (1.23–3.76) for the
GG genotype compared with the AA genotype. The respective
HRs among African-American women were 0.81 (0.62–1.06) and
1.08 (0.60–1.96). No other tested interaction reached statistical
significance.
Discussion
We report here that the GG genotype of rs10757274, which
increases susceptibility to CHD,1 is also associated with increased
risk of HF among whites in ARIC. This SNP was weakly associated
with prevalent carotid atherosclerosis among whites. No such
association was observed for incident ischaemic stroke or preva-
lent PAD. The results were similar for rs2383206 due to a high
correlation with rs10757274 among whites. To our knowledge,
this is the first report to examine an association between this
area of chromosome 9p21 and incident HF.
The association between the rs10757274 polymorphism and
CHD was first discovered in a genome-wide association study
which included ARIC data.1 This association, or that involving a
highly linked nearby SNP such as rs10757278,2 has been consist-
ently replicated.6,7,16– 23 Our finding for HF seems concordant
with these results for CHD, because HF is often a consequence
of CHD. Surprisingly, though, when we censored for incident
cases of CHD in addition to excluding prevalent CHD at baseline,
the association did not attenuate greatly. Thus, it can be speculated
that the GG genotype of rs10757274 may contribute to HF inde-
pendently of clinical CHD events. Yet, this should be interpreted
cautiously, because it is likely that unmeasured or unreported sub-
clinical ischaemia contributed to many ARIC HF events even after
censoring reported CHD occurrence. The relationship between
rs10757274 and HF should be confirmed by further studies,
along with a search for plausible mechanisms, such as possible
effect on myocardial remodelling.
Similar, but non-significant, associations were observed for HF
among African-Americans. Non-significant results could be
explained by smaller sample sizes, since only 32 HF events
occurred among African-Americans with the GG genotype.
Indeed, the HR of HF among African-Americans, namely 1.39
(0.94–2.08), was somewhat higher than in whites, although not
statistically significant (P ¼ 0.10). On the other hand, it is also poss-
ible that rs10757274 does not associate with CHD or HF in
African-Americans. The relatively low correlation (r2 ¼ 0.36)
between rs10757274 and rs2383206 in African-Americans
suggests that these SNPs are not tag-SNPs for the culprit genetic
variant responsible for CHD. The fact that these SNPs have not
linked to incident CHD in previous ARIC and Dallas Heart Study
analyses among African American,1 nor to the other atherosclero-
tic diseases presented here, may support this explanation. Unfortu-
nately, our study could not resolve this issue because of a very low
frequency of risk genotypes among African-Americans. A larger
study of African-Americans is needed to confirm our observation.
A very recent study reported that the rs1333049 SNP, which
was highly correlated with rs10757274 (r2 ¼ 0.89), was associated
with the prevalence and progression of carotid atherosclerosis.7
Though the number of cases was relatively small, they also
reported non-significant associations with CHD (HR for homozy-
gotes of risk allele ¼ 1.4, n ¼ 56) and cerebral/peripheral artery
events (HR ¼ 1.4, n ¼ 63). On the other hand, another study6
showed the rs10757278 SNP to be associated not only with
CHD but also with abdominal aortic and intracranial aneurysms
(OR  1.3). Consistent with our findings, that study also showed
little association with large artery atherosclerotic/embolic stroke
or PAD. Concordantly, some other case–control studies24,25
found no or weak associations of rs10757274, rs2383206, or
nearby SNPs with ischaemic stroke, though one found several hap-
lotypes of 9p21 SNPs that may increase ischaemic stroke risk.25
Another Finnish study showed no associations of rs1333049 SNP
with carotid IMT or impaired brachial artery flow-mediated dilata-
tion.26 Taken together, this area of chromosome 9p21 can be
speculated to contribute more to vascular remodelling or repair6
than to cerebral or peripheral atherosclerosis. Our results
showing no association of rs10757274 with PAD and ischaemic
stroke, as well as a weak association with carotid atherosclerosis,
may support this hypothesis. ARIC has quite limited information
on aneurysms (i.e. only unvalidated aortic aneurysm hospital dis-
charge diagnoses, validated subarachnoid haemorrhages and date
of hospitalization, and few cases especially in African-Americans).
In a supplementary analysis (not shown), we found no association
between rs10757274 and aneurysms in this limited data set: multi-
variable HR ¼ 1.19 (0.85–1.69) for AG and 1.16 (0.77–1.75) for
GG genotypes among whites.
Some limitations to our study warrant mentioning. Firstly, the
HF diagnosis was based on unvalidated hospitalized or fatal
events with HF ICD codes. Yet, previous evidence suggests
that most HF cases are eventually hospitalized and the validity of
HF ICD codes is high.27 Secondly, ankle–brachial blood pressure
index was assessed on a single leg, meaning the PAD diagnosis
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Table 2 Race-specific hazard and odds ratios (95% confidence intervals) of incident heart failure, stroke, and prevalent peripheral artery disease and carotid
atherosclerosis for rs10757274 genotypes, ARIC, 1987–2004
rs10757274
African-Americans Whites
AA AG GG P-value
for trenda
AA AG GG P-value
for trenda
Incidence
Number at risk (n) 2174 1149 176 2628 4913 2340
HF (n) 291 157 32 204 432 215
At risk (person-years) 32 975 17 250 2581 41 793 77 976 37 021
Age- and sex-adjusted HR 1.00 1.01 (0.83–1.22) 1.38 (0.96–1.99) 0.26 1.00 1.14 (0.97–1.35) 1.22 (1.01–1.48) 0.04
Multivariable HRb 1.00 0.96 (0.78–1.18) 1.39 (0.94–2.08) 0.48 1.00 1.17 (0.98–1.38) 1.30 (1.07–1.58) 0.008
HF censored at incident CHD 228 123 24 136 286 141
At risk (person-years) 32 059 16 806 2542 40 240 74 267 35 101
Age- and sex-adjusted HR 1.00 1.00 (0.80–1.25) 1.29 (0.85–1.97) 0.45 1.00 1.16 (0.94–1.42) 1.23 (0.97–1.56) 0.08
Multivariable HRb 1.00 0.94 (0.75–1.20) 1.40 (0.90–2.18) 0.56 1.00 1.17 (0.95–1.45) 1.28 (1.00–1.62) 0.046
Ischaemic stroke (n) 141 64 13 77 170 59
At risk (person-years) 31 529 16 607 2466 40 077 74 703 35 601
Age- and sex-adjusted HR 1.00 0.84 (0.63–1.13) 1.15 (0.65–2.03) 0.63 1.00 1.20 (0.92–1.57) 0.89 (0.63–1.25) 0.60
Multivariable HRb 1.00 0.83 (0.60–1.15) 1.12 (0.60–2.09) 0.59 1.00 1.23 (0.94–1.62) 0.93 (0.66–1.31) 0.79
Prevalence
PAD casesc 121 82 10 116 235 126
Number of participants (n) 2374 1274 198 2820 5312 2566
Age- and sex-adjusted OR 1.00 1.27 (0.95–1.70) 0.94 (0.49–1.83) 0.32 1.00 1.07 (0.86–1.35) 1.20 (0.92–1.55) 0.17
Multivariable ORb 1.00 1.17 (0.86–1.60) 0.68 (0.31–1.51) 0.93 1.00 1.01 (0.80–1.28) 1.10 (0.84–1.44) 0.49
Carotid atherosclerosis casesc 621 351 58 843 1643 834
Number of participants (n) 2191 1148 184 2757 5212 2517
Age- and sex-adjusted OR 1.00 1.10 (0.93–1.29) 1.08 (0.78–1.51) 0.29 1.00 1.05 (0.95–1.17) 1.14 (1.01–1.28) 0.04
Multivariable ORb 1.00 1.08 (0.91–1.29) 1.03 (0.71–1.48) 0.48 1.00 1.02 (0.92–1.14) 1.14 (1.00–1.29) 0.047
Carotid IMT (meand and 95% CI, mm)
Age- and sex-adjusted 0.73 (0.72–0.73) 0.73 (0.72–0.74) 0.73 (0.71–0.76) 0.36 0.72 (0.72–0.73) 0.73 (0.72–0.73) 0.72 (0.71–0.73) 0.87
Multivariableb 0.73 (0.72–0.73) 0.73 (0.72–0.74) 0.73 (0.70–0.75) 0.62 0.72 (0.72–0.73) 0.72 (0.72–0.73) 0.72 (0.72–0.73) 0.87
HR, hazard ratio; HF, heart failure; CHD, coronary heart disease; PAD, peripheral artery disease; OR, odds ratio; IMT, intima-media thickness; CI, confidence interval.
aTrends were tested by additive models (assigning 0 for AA, 1 for AG, and 2 for GG genotypes).
bAdjusted for age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and high-density lipoprotein cholesterols, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level, and
sports index. Subjects missing covariates were eliminated.
cPAD was defined as presence of claudication or ankle–brachial index ,0.9; carotid atherosclerosis was IMT .1.0 mm or the presence of plaque or shadowing.







would have high specificity but some PAD cases may have been
missed. However, since the number of true negatives (no PAD)
greatly outnumbers the small number of expected false negatives,
this misclassification should not affect the 9p21 SNP association
with PAD very much. Thirdly, although larger than for
African-Americans, the numbers of ischaemic strokes (n ¼ 306)
and PAD (n ¼ 477) among whites were relatively small. Thus, it
is possible that we missed a modest association of 9p21 SNPs
with ischaemic stroke or PAD, as the previous study found a
weak association (OR ¼ 1.14) for PAD.6 Fourthly, the genotyping
success rates of 92.8–96.2% were not very high, which could
potentially cause genotyping bias and might obscure associations.
Last, the present study could not separate different aetiologies of
HF. Although the observed gene–HF associations seemed to be
independent of CHD, this observation is not definitive because
we undoubtedly missed some silent or subclinical CHD, as dis-
cussed earlier. Replication in other populations is needed to
confirm whether our finding of this gene–HF association is truly
independent of CHD.
In conclusion, in this prospective study, the GG genotype of
rs10757274 on chromosome 9p21 was associated with increased
risk of HF among whites independently of its association with
CHD. This SNP was not appreciably associated with ischaemic
stroke, PAD, or carotid atherosclerosis. Our observation might
support the hypothesis that this area of chromosome 9p21 con-
tributes to cardiovascular diseases partly via non-atherosclerotic
pathways.
Supplementary material
Supplementary Material is available at European Heart Journal
Online.
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